Non-coding recurrent mutations in chronic lymphocytic leukaemiaXosé S. Puente, María José Terol, Sı́lvia Beà et al.|Nature|2015Cited by 851
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trialAleix Prat, Joaquín Gavilá, Neus Ferrer et al.|The Lancet Oncology|2019Cited by 199
CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1− mantle cell lymphomaDavid Martin‐García, Sı́lvia Beà, Alba Navarro et al.|Blood|2018Cited by 112
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluationAleix Prat, PierFranco Conte, Valentina Guarneri et al.|The Lancet Oncology|2020Cited by 75
Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancerMercedes Marín‐Aguilera, Laia Paré, Pedro Jares et al.|ESMO Open|2024Cited by 27